SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-037186
Filing Date
2021-03-16
Accepted
2021-03-16 16:53:56
Documents
12
Period of Report
2021-03-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm219821d1_8k.htm   iXBRL 8-K 25284
  Complete submission text file 0001104659-21-037186.txt   198986

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20210315.xsd EX-101.SCH 3193
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20210315_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20210315_pre.xml EX-101.PRE 22715
5 EXTRACTED XBRL INSTANCE DOCUMENT tm219821d1_8k_htm.xml XML 3625
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 21746628
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences